Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer

NCT03926338 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

270

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Mismatch Repair-deficient (dMMR)
Microsatellite Instability-high (MSI-H)
Neoadjuvant Therapy

Interventions

DRUG: Neoadjuvant toripalimab plus celecoxib for 6 cycles
DRUG: Neoadjuvant toripalimab monotherapy for 6 cycles
DRUG: Neoadjuvant toripalimab plus celecoxib for 12 cycles
DRUG: Neoadjuvant toripalimab monotherapy for 12 cycles
DRUG: Toripalimab plus celecoxib as neoadjuvant or definitive therapy

Sponsor

Sun Yat-sen University